4 years of burn with current cash, which doesn’t include a 1.8B check from BMY which pushes the runway north of a decade
well…
http://ir.nektar.com/news-releases/news-release-details/nekt…
Cash and investments in marketable securities at March 31, 2018 were $333.8 million as compared to $353.2 million at December 31, 2017. This does not include the $1.0 billion upfront payment and $850.0 million share purchase proceeds received on April 3, 2018, as a result of our new Bristol-Myers Squibb collaboration…
(I count 2.2b approximately)
In the first quarter of 2018, net loss was $95.8 million
So, I count 400m/yr, so, 4 years worth; which does include the 1.8b check, but does NOT include increased expenses for much larger clinical trials. Though it also does not include any checks for 181, which they have already said they are actively seeking to unload. They probably have 2 years worth of cash when you take into account that their R&D expenses will increase ALOT from current rates given all the trials they have going on. Dont be surprised if they trim a few trials when costs start ramping up.